top of page
Embryonic Stem Cells


Aiming to develop curative immunotherapies for all cancer patients


Immunotherapies have revolutionized the treatment of cancer, resulting in cures in subsets of cancer patients, yet remain ineffective for the majority of patients. We are developing methods to extend life-saving immunotherapies to all individuals struck by cancer. Our work aims to address the major bottlenecks preventing wider use of immunotherapies and is grounded in first principles: discovering tumor-specific targets using multi-omics approaches and engineering target-specific immune receptors using combined computational and experimental techniques.  Our team operates at the dynamic crossroads of genomics, proteomics, immunology, antibody engineering, and computational biology, developing and implementing cutting-edge technologies to safely and effectively treat cancer. We are generating a pipeline of new therapies for cancer patients in need and developing technologies to enable personalized immunotherapies for any cancer patient. Our novel class of peptide-centric (PC)-CAR T cells potently eradicate aggressive tumors and are entering clinical trials in 2024.

Engineered PC-CAR T cell receptor



The Yarmarkovich lab will be housed in the brand new state-of-the-art facilities at the CURE building located in the heart of Manhattan.

Image by Florian Wehde

“Do not go where the path may lead, go instead where there is no path and leave a trail.”

-Ralph Waldo Emerson

bottom of page